Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: A systematic review

Liu, Qing; Feng, Chen-Chen; Wang, Er-Man; Yan, Xiu-Juan; Chen, Shengliang

doi:10.3748/wjg.v19.i47.9111

Cited by 21 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, their effect is modest. A systematic review that compared the efficacy of mosapride plus PPI with PPI monotherapy in GORD did not show any benefit 98. The addition of mosapride to PPI was shown to improve symptoms in patients with GORD with dysmotility symptoms 99–101.…”

Section: Resultsmentioning

confidence: 97%

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

Fock

Talley

Goh

et al. 2016

Gut

153

214

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 97%

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

Fock

Talley

Goh

et al. 2016

Gut

153

214

View full text Add to dashboard Cite

“…Mosapride is a 5-HT 4 receptor agonist and can stimulate upper gastrointestinal movement [ 34 ], accelerate gastric emptying [ 35 ] and colonic motility [ 36 , 37 ], and improve stool frequency and consistency, especially in patients with irritable bowel syndrome with constipation (IBS-C) [ 38 ] and/or functional constipation [ 37 ]. Consequently, the effects of EA during the treatment and follow-up periods can be more accurately revealed by using mosapride as the controlled intervention.…”

Section: Discussionmentioning

confidence: 99%

Electroacupuncture for Functional Constipation: A Multicenter, Randomized, Control Trial

Zheng

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background and Aim. To investigate the efficacy and safety of electroacupuncture (EA) with different current intensities for functional constipation (FC) and to assess whether the effects of EA with different current intensities are superior to the mosapride. Methods. Patients with FC were randomly divided into low current intensity group (LCI), high current intensity group (HCI), and mosapride group (MC). The primary outcome was three or more spontaneous bowel movements (SBMs) per week and an increase of one or more SBMs from baseline during at least 3 of the 4 weeks. Results. The primary outcome was reached by 53.45%, 66.15%, and 52.24% of the patients who received LCI, HCI, and mosapride, respectively. EA can significantly improve the weekly SBMs and stool consistency and reduce straining severity (p < 0.0001, all). HCI improved the quality of life better than mosapride (p < 0.05) and reduced the proportion of severe constipation more than LCI and mosapride (p < 0.05, both). Conclusions. EA is effective and safe at both current intensities for FC; therapeutic effects of LCI and HCI are not superior to mosapride. EA is superior to mosapride in improving patients' life quality and satisfaction level of treatment; EA has fewer adverse events than mosapride.

show abstract

“…35–37 These studies were included in a 2013 systematic review reporting that mosapride combination therapy with PPI is no more effective than PPI alone. 38 However, in a subgroup analysis, patients with more severe symptoms experienced a slight benefit compared to placebo. 36 Two subsequent studies similarly found no improvement in GERD symptoms with combination mosapride therapy, also noting lower response rates in NERD as compared to EE.…”

Section: Adjunctive Medical Therapiesmentioning

confidence: 99%

A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease

Hillman

Yadlapati

Thuluvath

et al. 2017

Diseases of the Esophagus

View full text Add to dashboard Cite

Introduction Up to 40% of patients report persistent gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy. This review outlines the evidence for medical therapy for PPI non-responsive GERD. Materials and Methods A literature search for GERD therapies from 2005–2015 in PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews identified unique 2928 citations. Of those, 40 unique articles specific to the impact of PPI metabolizer genotype on PPI response and the use adjunctive medical therapies were identified. Results Thirteen articles reported impacts on CYP genotypes on PPI metabolism demonstrating lower endoscopic healing rates in extensive metabolizers; however, outcomes across genotypes were more uniform with more CYP independent PPIs rabeprazole and esomeprazole. Twenty-seven publications on 11 adjunctive medications showed mixed results for adjunctive therapies including nocturnal histamine-2 receptor antagonists, promotility agents, transient lower esophageal sphincter relaxation inhibitors, and mucosal protective agents. Discussion Utilizing PPI metabolizer genotype or switching to a CYP2C19 independent PPI is a simple and conservative measure that may be useful in the setting of incomplete acid suppression. The use of adjunctive medications can be considered particularly when the physiologic mechanism for PPI non-response is suspected. Future studies using adjunctive medications with improved study design and patient enrollment are needed to better delineate medical management options before proceeding to anti-reflux interventions.

show abstract

Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: A systematic review

Abstract: Mosapride combined therapy is not more effective than PPI alone as first-line therapy. Whether it is effective in PPI-resistant patients needs to be determined.

Cited by 21 publications

References 39 publications

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

Electroacupuncture for Functional Constipation: A Multicenter, Randomized, Control Trial

A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease

Contact Info

Product

Resources

About